Medtronic closes 1st phase of Symplicity renal denervation feasibility trial

October 3, 2012 by MassDevice staff

Medtronic said the 1st phase of a small trial of the next iteration of its Symplicity device for treating high blood pressure showed a 100% success rate.


Medtronic (NYSE:MDT) said it's closed the 1st phase of a feasibility trial for its next-generation Symplicity renal denervation device for high blood pressure.

The 9-patient trial delivered a 100% acute success rate in accessing the renal arteries and delivering the therapy, according to a press release.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.